Literature DB >> 32030098

Incidence and prevalence of common respiratory pathogens before and after implementation of the Cystic Fibrosis Foundation Infection Prevention and Control Guideline.

Christy Kim1, Elizabeth delaRiva-Velasco1, Arvind Budhram1, Folashade Farri1, Daniel Krich1, Sheila S Nolan2, Suzette Gjonaj1, Lisa Paul3, Allen J Dozor1, John J Welter1.   

Abstract

BACKGROUND: The 2013 Cystic Fibrosis Foundation's Infection Prevention and Control Guideline (CFF IP&C) was developed to reduce the risk of acquisition and transmission of respiratory pathogens in patients with cystic fibrosis (CF).
OBJECTIVE: We hypothesised that the incidence of common CF respiratory pathogens would decrease at our centre after implementation of the guideline.
METHODS: All patients with CF seen at our centre from August 2012 through August 2017 who had respiratory cultures were included. Patients were excluded from incidence analysis if they did not have at least one culture per year. Quarterly data were collected for one year before and three years after implementation of the guidelines to determine the incidence and prevalence of seven organisms commonly found in respiratory cultures of patients with CF.
RESULTS: Quarterly and annual incidence and prevalence rates of common organisms did not change during the study period. DISCUSSION: There were no significant differences in the incidence or prevalence of common respiratory organisms in the first three years after implementation of the CF IP&C guideline. Long-term follow-up is needed to determine if changes occur over time.
© The Author(s) 2019.

Entities:  

Keywords:  Cystic fibrosis; infection control; infection prevention; patient-to-patient transmission

Year:  2019        PMID: 32030098      PMCID: PMC6978569          DOI: 10.1177/1757177419872538

Source DB:  PubMed          Journal:  J Infect Prev        ISSN: 1757-1782


  16 in total

1.  Air contamination with bacteria in cystic fibrosis clinics: implications for prevention strategies.

Authors:  Jonathan B Zuckerman; Sarah A Clock; B Stephen Prato; James J McDevitt; Juyan Julia Zhou; Laurie W Leclair; F Lee Lucas; Lisa Saiman
Journal:  Am J Respir Crit Care Med       Date:  2015-03-01       Impact factor: 21.405

2.  Molecular epidemiological surveillance of multidrug-resistant Pseudomonas aeruginosa isolates in a pediatric population of patients with cystic fibrosis and determination of risk factors for infection with the Houston-1 strain.

Authors:  Ruth Ann Luna; Laura A Millecker; C Renee Webb; Sally K Mason; Elaine M Whaley; Jeffrey R Starke; Peter W Hiatt; James Versalovic
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

3.  Infection prevention and control guideline for cystic fibrosis: 2013 update.

Authors:  Lisa Saiman; Jane D Siegel; John J LiPuma; Rebekah F Brown; Elizabeth A Bryson; Mary Jo Chambers; Veronica S Downer; Jill Fliege; Leslie A Hazle; Manu Jain; Bruce C Marshall; Catherine O'Malley; Suzanne R Pattee; Gail Potter-Bynoe; Siobhan Reid; Karen A Robinson; Kathryn A Sabadosa; H Joel Schmidt; Elizabeth Tullis; Jennifer Webber; David J Weber
Journal:  Infect Control Hosp Epidemiol       Date:  2014-07-01       Impact factor: 3.254

4.  Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures.

Authors:  Adrienne P Savant; Catherine O'Malley; Stacy Bichl; Susanna A McColley
Journal:  BMJ Qual Saf       Date:  2014-04       Impact factor: 7.035

5.  Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic.

Authors:  Amanda L Griffiths; Danielle F Wurzel; Phil J Robinson; Rosemary Carzino; John Massie
Journal:  J Cyst Fibros       Date:  2011-09-09       Impact factor: 5.482

6.  Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.

Authors:  Elizabeth L Salsgiver; Aliza K Fink; Emily A Knapp; John J LiPuma; Kenneth N Olivier; Bruce C Marshall; Lisa Saiman
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

7.  Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales.

Authors:  Fiona W Scott; Tyrone L Pitt
Journal:  J Med Microbiol       Date:  2004-07       Impact factor: 2.472

8.  Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis.

Authors:  Giuseppe Valenza; Dennis Tappe; Doris Turnwald; Matthias Frosch; Corinne König; Helge Hebestreit; Marianne Abele-Horn
Journal:  J Cyst Fibros       Date:  2007-08-13       Impact factor: 5.482

9.  Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic.

Authors:  K Muhdi; F P Edenborough; L Gumery; S O'Hickey; E G Smith; D L Smith; D E Stableforth
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

10.  Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis.

Authors:  Luke D Knibbs; Graham R Johnson; Timothy J Kidd; Joyce Cheney; Keith Grimwood; Jacqueline A Kattenbelt; Peter K O'Rourke; Kay A Ramsay; Peter D Sly; Claire E Wainwright; Michelle E Wood; Lidia Morawska; Scott C Bell
Journal:  Thorax       Date:  2014-04-17       Impact factor: 9.139

View more
  1 in total

Review 1.  Immunomodulation in Cystic Fibrosis: Why and How?

Authors:  Vincent D Giacalone; Brian S Dobosh; Amit Gaggar; Rabindra Tirouvanziam; Camilla Margaroli
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.